protein kinase B

protein kinase B
Name	Protein kinase B
Other names	Akt
Family	AGC kinase
Location	Cytoplasm, Plasma membrane, Nucleus

protein kinase B

Protein kinase B is a serine/threonine kinase central to growth and survival signaling in mammalian cells. Discovered through studies of oncogenic transformation and insulin signaling, it integrates inputs from receptor tyrosine kinases, G protein‑coupled receptors, and nutrient sensors to regulate metabolism, proliferation, and apoptosis. Aberrant regulation of its isoforms underlies many human diseases, making it a major focus of academic, pharmaceutical, and clinical research.

Introduction

Protein kinase B occupies a pivotal node in pathways initiated by Epidermal growth factor receptor, Insulin receptor, Platelet-derived growth factor receptor, and downstream effectors such as Phosphoinositide 3-kinase and Phosphatase and tensin homolog. Work by groups at institutions including Harvard University, University of California, San Diego, and Cold Spring Harbor Laboratory clarified its role in linking extracellular cues to intracellular responses. The kinase is studied across fields from developmental biology at Stanford University to oncology programs at Memorial Sloan Kettering Cancer Center and metabolic research at Joslin Diabetes Center.

Structure and Isoforms

Protein kinase B comprises three mammalian isoforms encoded by the genes AKT1, AKT2, and AKT3, each with conserved domains: an N‑terminal pleckstrin homology (PH) domain, a central kinase domain, and a C‑terminal regulatory tail. Structural studies using cryo‑EM and X‑ray crystallography at facilities such as European Molecular Biology Laboratory and Diamond Light Source revealed PH domain interactions with phosphoinositides produced by Phosphoinositide 3-kinase, and conformational shifts that expose the activation loop. Isoform expression varies: AKT1 is broadly expressed and implicated in growth regulation, AKT2 is enriched in insulin‑responsive tissues such as liver and muscle studied at Karolinska Institutet, and AKT3 predominates in brain development, investigated at centers like Max Planck Society. Post‑translational modifications include phosphorylation, ubiquitination, and methylation; proteomic screens at Broad Institute and Scripps Research identified regulatory sites and interacting partners.

Activation and Regulation

Activation begins with recruitment of the PH domain to membranes enriched in phosphatidylinositol (3,4,5)-trisphosphate generated by Phosphoinositide 3-kinase after ligand binding to receptors like Insulin receptor or Epidermal growth factor receptor. Membrane localization permits phosphorylation by upstream kinases such as PDK1 at the activation loop and by mTOR complex 2 at the hydrophobic motif, events characterized in biochemical studies at Massachusetts Institute of Technology and University of Oxford. Negative regulation occurs via lipid phosphatases such as Phosphatase and tensin homolog, serine/threonine phosphatases including Protein phosphatase 2A, and E3 ligases mapped by teams at Cold Spring Harbor Laboratory and University of Cambridge. Feedback mechanisms link AKT signaling with transcription factors studied at Princeton University and stress pathways involving AMP-activated protein kinase, ensuring context‑dependent modulation.

Cellular Functions and Signaling Pathways

AKT controls metabolic programs by phosphorylating enzymes and transcriptional regulators involved in glucose uptake, glycogen synthesis, and lipid metabolism studied in models from University of California, San Francisco to Yale University. It promotes cell survival through inhibition of pro‑apoptotic factors such as BAD and regulators of the intrinsic apoptotic pathway researched at Johns Hopkins University. AKT signaling drives cell cycle progression via effects on cyclin‑dependent kinase inhibitors and the mTOR pathway, with implications elucidated in cancer centers like Dana-Farber Cancer Institute and MD Anderson Cancer Center. In the nervous system, AKT isoforms regulate neuronal growth and synaptic plasticity, topics pursued at Salk Institute and Cold Spring Harbor Laboratory. Crosstalk with pathways governed by Ras, Wnt, and Notch integrates AKT output into developmental and homeostatic programs.

Role in Disease and Therapeutic Targeting

Dysregulation of AKT signaling contributes to oncogenesis, metabolic disorders, and neurodegeneration. Somatic alterations in AKT genes and upstream regulators are frequent in cancers profiled by consortia such as The Cancer Genome Atlas and trials at National Cancer Institute have targeted this axis. AKT hyperactivation promotes tumor growth, resistance to apoptosis, and therapy resistance investigated in clinical programs at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center. In metabolic disease, impaired AKT signaling underlies insulin resistance studied at Joslin Diabetes Center and implicated in type 2 diabetes cohorts at Mayo Clinic. Therapeutic strategies include ATP‑competitive inhibitors, allosteric inhibitors, and isoform‑selective compounds developed by pharmaceutical companies like Novartis, AstraZeneca, and Pfizer and tested in phase I–III trials coordinated by organizations such as European Medicines Agency and Food and Drug Administration. Neuroprotective roles of AKT make it a candidate target in neurodegenerative disease research at National Institutes of Health and academic centers worldwide.

Experimental Methods and Research Tools

AKT research employs techniques ranging from genetic models—knockout mice generated at facilities like Jackson Laboratory—to high‑throughput phosphoproteomics performed at Proteomics Center, Broad Institute. Common assays include Western blotting with phospho‑specific antibodies developed by vendors and characterized in labs at Stanford University, kinase activity assays using peptide substrates, and live‑cell imaging of membrane recruitment with fluorescent fusion proteins used in microscopy cores at Max Planck Society. Chemical biology approaches deploy small‑molecule inhibitors and PROTACs synthesized in academic‑industry collaborations at Scripps Research and assayed in preclinical models at University College London. CRISPR screens at institutions such as Broad Institute map genetic dependencies, while clinical biomarker studies at Mayo Clinic and Memorial Sloan Kettering Cancer Center evaluate pathway activity in patient samples.

Category:Protein kinases